Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Inclusion Criteria:

• Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3months or ≥ 2 flares within the previous 12 months.
• Screening and baseline IGA-CHE 3 or 4.
• Baseline CHE-related Itch NRS ≥ 4.
• Recent history (within the past 1 year of baseline) of inadequate response totreatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), ororal alitretinoin; or intolerance or contraindication to TCS or TCI or oralalitretinoin.
• Willingness to avoid pregnancy or fathering children based on the criteria below.

Exclusion Criteria:

• Known triggers for CHE (allergic or irritant, such as those identified by previouspatch tests) cannot be avoided during the course of this study.
• Participants who have an unstable course of AD (spontaneously improving or rapidlydeteriorating) as determined by the investigator in the 4 weeks prior to baseline.
• Participants with concurrent conditions and history of other diseases such as otheractive skin disease or infection on the hands; immunocompromised; chronic or acuteinfection requiring systemic treatments; active acute skin infection; otherconcomitant skin conditions that may interfere with study assessments or compromiseparticipant safety; other types of eczema; chronic asthma requiring high dose ofinhaled corticosteroids; current or history of hepatitis B or C virus infection.
• Any serious illness or medical, physical, or psychiatric condition(s) that, in theinvestigator's opinion, would interfere with full participation in the study,including administration of study drug and attending required study visits; pose asignificant risk to the participant; or interfere with interpretation of study data.
• Laboratory values outside of the protocol-defined criteria.
• Use of protocol-defined treatments within the indicated washout period beforebaseline.
• Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4weeks before baseline.
• Pregnant or lactating participants, or those considering pregnancy during the periodof their study participation.
• Further exclusion criteria apply.